NVO vs. LLY
Compare and contrast key facts about Novo Nordisk A/S (NVO) and Eli Lilly and Company (LLY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NVO or LLY.
Correlation
The correlation between NVO and LLY is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NVO vs. LLY - Performance Comparison
Key characteristics
NVO:
-0.70
LLY:
0.52
NVO:
-0.80
LLY:
0.93
NVO:
0.89
LLY:
1.12
NVO:
-0.55
LLY:
0.67
NVO:
-1.48
LLY:
1.67
NVO:
17.13%
LLY:
9.68%
NVO:
36.27%
LLY:
31.10%
NVO:
-71.31%
LLY:
-68.27%
NVO:
-46.24%
LLY:
-24.28%
Fundamentals
NVO:
$352.92B
LLY:
$652.65B
NVO:
$2.93
LLY:
$9.29
NVO:
26.86
LLY:
78.12
NVO:
1.28
LLY:
0.72
NVO:
$204.72B
LLY:
$31.51B
NVO:
$173.22B
LLY:
$25.63B
NVO:
$108.42B
LLY:
$9.48B
Returns By Period
In the year-to-date period, NVO achieves a -8.52% return, which is significantly lower than LLY's -5.99% return. Over the past 10 years, NVO has underperformed LLY with an annualized return of 15.65%, while LLY has yielded a comparatively higher 28.47% annualized return.
NVO
-8.52%
-25.74%
-39.95%
-26.03%
22.75%
15.65%
LLY
-5.99%
-5.10%
-15.11%
17.18%
40.98%
28.47%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NVO vs. LLY — Risk-Adjusted Performance Rank
NVO
LLY
NVO vs. LLY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NVO vs. LLY - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 1.83%, more than LLY's 0.72% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 1.83% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
LLY Eli Lilly and Company | 0.72% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.95% | 2.46% | 2.77% | 2.37% | 2.84% |
Drawdowns
NVO vs. LLY - Drawdown Comparison
The maximum NVO drawdown since its inception was -71.31%, roughly equal to the maximum LLY drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for NVO and LLY. For additional features, visit the drawdowns tool.
Volatility
NVO vs. LLY - Volatility Comparison
Novo Nordisk A/S (NVO) has a higher volatility of 21.75% compared to Eli Lilly and Company (LLY) at 10.25%. This indicates that NVO's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NVO vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities